Ciphero | $2,500,000 | (Dec 23, 2025)
beycome | $2,500,000 | (Dec 23, 2025)
Givefront | $2,000,000 | (Dec 23, 2025)
MimiVax, LLC
United States
- Buffalo, NY
- 10/12/2021
- Unknown
- $5,000,000
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer.
SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2 clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) as well as Phase 1 in Neuro-Endocrine Tumors (NET)
- Industry Pharmaceutical Manufacturing
- Website https://www.mimivax.com/
- LinkedIn https://www.linkedin.com/company/mimivax-llc/
Related People
Michael CiesielskiFounder
United States -
Buffalo-Niagara Falls Area
At MimiVax, our mission is to disrupt cancer. To increase survival and send hope through the development of highly innovative immunotherapies aimed at improving patient's lives.
StretchSense | $2,300,000 | (Dec 23, 2025)
ZeroPhase | $6,800,000 | (Dec 23, 2025)
Peripheral Labs | $3,600,000 | (Dec 23, 2025)
Ethereal Exploration Guild | $21,000,000 | (Dec 23, 2025)
LatentForce | $1,700,000 | (Dec 23, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Amphix Bio | $12,500,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)